Company profile for Hillstream BioPharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Hillstream BioPharma is a development stage company focused on rare cancers. By harnessing a weakness in tumors to preferentially concentrate Hillstream’s proprietary QuatramerTM technology, we are developing targeted cancer therapies. The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into the tumor’s genome. We w...
Hillstream BioPharma is a development stage company focused on rare cancers. By harnessing a weakness in tumors to preferentially concentrate Hillstream’s proprietary QuatramerTM technology, we are developing targeted cancer therapies. The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into the tumor’s genome. We will work to improve the lives of patients as we rapidly move into the clinic to treat small cell lung cancer, soft-tissue sarcomas and other high unmet need rare cancers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
245 Main Street Suite 204 Chester, NJ 07930
Telephone
Telephone
1-302-743-2995
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2023/09/11/2741034/0/en/Hillstream-Enters-into-an-Exclusive-Option-Agreement-to-Acquire-a-Clinical-Stage-Asset-for-Chronic-Pruritis.html

GLOBENEWSWIRE
11 Sep 2023

https://www.globenewswire.com//news-release/2023/09/08/2740295/0/en/Hillstream-BioPharma-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference-September-11-13.html

GLOBENEWSWIRE
08 Sep 2023

https://www.globenewswire.com/news-release/2023/08/09/2721669/0/en/Hillstream-BioPharma-to-Present-at-the-Sidoti-Micro-Cap-Virtual-Conference-on-August-16-17-2023.html

GLOBENEWSWIRE
09 Aug 2023

https://www.globenewswire.com/news-release/2023/07/20/2708133/0/en/Hillstream-Advances-Next-Gen-Multispecific-Antibodies-for-Solid-Tumors-with-Lead-HER2-HER3-Program-HSB-3215.html

GLOBENEWSWIRE
20 Jul 2023

https://www.globenewswire.com/news-release/2023/07/10/2701788/0/en/Hillstream-BioPharma-Announces-Strategic-Reprioritization-of-Pipeline-to-Targeting-HER2-HER3-Solid-Tumors-via-Bispecific-and-ADC-Antibodies-and-Biologics.html

GLOBENEWSWIRE
10 Jul 2023

https://www.globenewswire.com/news-release/2023/07/06/2700331/0/en/Hillstream-BioPharma-Licenses-Technology-to-Develop-Proprietary-HER2-and-HER3-Antibody-Drug-Conjugates-against-Drug-Resistant-Breast-Lung-Gastric-and-Ovarian-Cancers.html

GLOBENEWSWIRE
06 Jul 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty